Navigation Links
Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder


Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced the awarding of a $340K grant from the National Institute of Mental Health for the further advancement of the company’s 3-month risperidone product (DLP-114). The product is based on Delpor’s Prozor technology and is expected to deliver therapeutic levels of risperidone for a period of at least 3 months in order to improve medication adherence.

"We are honored to receive this grant award and extremely grateful to the National Institute of Mental Health for believing in our vision." said Tassos Nicolaou, President and CEO of Delpor. "We look forward to employing these new funds to further develop our risperidone program which is expected to offer tremendous treatment benefits to patients suffering from schizophrenia or bipolar disorder.”

Lack of medication adherence is one of the most frequently cited unmet needs in the treatment of schizophrenia and bipolar disorder and it is a major reason that neuroleptic drugs are not more effective in keeping people with schizophrenia out of the hospital. It is estimated that lack of medication adherence accounts for approximately 40% of all relapse. With each successive relapse, the patient’s long-term prognosis deteriorates and previous level of functioning is rarely achieved. Current long acting systems have shown some improvement, but also have certain limitations.

Tassos Nicolaou continued: “DLP-114 is expected to overcome several limitations of the current depot injections. More specifically, the system is expected to further improve medication adherence by extending the release from a couple of weeks to several months, offer full reversibility in case the patient has a treatment related adverse event, and reduce side effects by providing a consistent and superior pharmacokinetic profile.” Mr. Nicolaou concluded by saying: “This is not just about improving medication adherence. It is about addressing an important unmet medical need and improving clinical outcomes for patients suffering from a chronic and disabling brain disorder.”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of antipsychotics (in order to improve medication adherence, tolerance, and safety) as well as biologics in order to improve patient safety and convenience. The company’s lead products include 3-month formulations of Risperidone, Paliperidone, and Interferon-alpha. Additional information about the company can be found at

About DLP-114
Delpor’s DLP-114 is a small titanium reservoir designed for subcutaneous implantation and loaded with a proprietary formulation of risperidone. The product is designed to provide a constant therapeutic dose of risperidone each day for a total period of 3-6 months. Additional features include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Delpor, Inc.
Tassos Nicolaou, President and CEO
Phone: 415-480-6873
Fax:     415-480-6871

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Produce Safety Researchers Awarded by ABC Research Laboratories
2. Cohera Medical Awarded Platform Patent on its Biodegradable Adhesive Technology
3. CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals
4. Chemring Detection Systems Awarded $9M for Biological Detection Systems
5. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
6. Chemring Detection Systems Awarded $500k for Strategic Research and Development
7. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
8. Sloan Research Fellowships Awarded to 126 Young Scholars
9. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
10. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
Related Image:
Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... 2017 , ... At its national board meeting in North Carolina, ARCS® ... Departments of Physics and Astronomy, has been selected for membership in ARCS Alumni ... the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the ... in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):